Cargando…

Impact of diabetes mellitus on ischemic cardiomyopathy. Five-year follow-up. REVISION-DM trial

BACKGROUND: Patients with ischemic cardiomyopathy and severe left ventricular dysfunction have a worse survival prognosis than patients with preserved ventricular function. The role of diabetes in the long-term prognosis of this patient group is unknown. This study investigated whether the presence...

Descripción completa

Detalles Bibliográficos
Autores principales: Hueb, Thiago, Rocha, Mauricio S., Siqueira, Sergio F., Nishioka, Silvana Angelina D´Orio, Peixoto, Giselle L., Saccab, Marcos M., Lima, Eduardo Gomes, Garcia, Rosa Maria Rahmi, Ramires, José Antonio F., Kalil Filho, Roberto, Martinelli Filho, Martino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856370/
https://www.ncbi.nlm.nih.gov/pubmed/29568331
http://dx.doi.org/10.1186/s13098-018-0320-y
_version_ 1783307294740578304
author Hueb, Thiago
Rocha, Mauricio S.
Siqueira, Sergio F.
Nishioka, Silvana Angelina D´Orio
Peixoto, Giselle L.
Saccab, Marcos M.
Lima, Eduardo Gomes
Garcia, Rosa Maria Rahmi
Ramires, José Antonio F.
Kalil Filho, Roberto
Martinelli Filho, Martino
author_facet Hueb, Thiago
Rocha, Mauricio S.
Siqueira, Sergio F.
Nishioka, Silvana Angelina D´Orio
Peixoto, Giselle L.
Saccab, Marcos M.
Lima, Eduardo Gomes
Garcia, Rosa Maria Rahmi
Ramires, José Antonio F.
Kalil Filho, Roberto
Martinelli Filho, Martino
author_sort Hueb, Thiago
collection PubMed
description BACKGROUND: Patients with ischemic cardiomyopathy and severe left ventricular dysfunction have a worse survival prognosis than patients with preserved ventricular function. The role of diabetes in the long-term prognosis of this patient group is unknown. This study investigated whether the presence of diabetes has a long-term impact on left ventricular function. METHODS: Patients with coronary artery disease who underwent coronary artery bypass graft surgery, percutaneous coronary intervention, or medical therapy alone were included. All patients had multivessel disease and left ventricular ejection fraction measurements. Overall mortality, nonfatal myocardial infarction, stroke, and additional interventions were investigated. RESULTS: From January 2009 to January 2010, 918 consecutive patients were selected and followed until May 2015. They were separated into 4 groups: G1, 266 patients with diabetes and ventricular dysfunction; G2, 213 patients with diabetes without ventricular dysfunction; G3, 213 patients without diabetes and ventricular dysfunction; and G4, 226 patients without diabetes but with ventricular dysfunction. Groups 1, 2, 3, and 4, respectively, had a mortality rate of 21.6, 6.1, 4.2, and 10.6% (P < .001); nonfatal myocardial infarction of 5.3, .5, 7.0, and 2.6% (P < .001); stroke of .40, .45, .90, and .90% (P = NS); and additional intervention of 3.8, 11.7, 10.3, and 2.6% (P < .001). CONCLUSION: In this sample, regardless of the treatment previously received patients with or without diabetes and preserved ventricular function experienced similar outcomes. However, patients with ventricular dysfunction had a worse prognosis compared with those with normal ventricular function; patients with diabetes had greater mortality than patients without diabetes. Trial registration http://www.controlled-trials.com. Registration Number: ISRCTN66068876
format Online
Article
Text
id pubmed-5856370
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58563702018-03-22 Impact of diabetes mellitus on ischemic cardiomyopathy. Five-year follow-up. REVISION-DM trial Hueb, Thiago Rocha, Mauricio S. Siqueira, Sergio F. Nishioka, Silvana Angelina D´Orio Peixoto, Giselle L. Saccab, Marcos M. Lima, Eduardo Gomes Garcia, Rosa Maria Rahmi Ramires, José Antonio F. Kalil Filho, Roberto Martinelli Filho, Martino Diabetol Metab Syndr Letter to the Editor BACKGROUND: Patients with ischemic cardiomyopathy and severe left ventricular dysfunction have a worse survival prognosis than patients with preserved ventricular function. The role of diabetes in the long-term prognosis of this patient group is unknown. This study investigated whether the presence of diabetes has a long-term impact on left ventricular function. METHODS: Patients with coronary artery disease who underwent coronary artery bypass graft surgery, percutaneous coronary intervention, or medical therapy alone were included. All patients had multivessel disease and left ventricular ejection fraction measurements. Overall mortality, nonfatal myocardial infarction, stroke, and additional interventions were investigated. RESULTS: From January 2009 to January 2010, 918 consecutive patients were selected and followed until May 2015. They were separated into 4 groups: G1, 266 patients with diabetes and ventricular dysfunction; G2, 213 patients with diabetes without ventricular dysfunction; G3, 213 patients without diabetes and ventricular dysfunction; and G4, 226 patients without diabetes but with ventricular dysfunction. Groups 1, 2, 3, and 4, respectively, had a mortality rate of 21.6, 6.1, 4.2, and 10.6% (P < .001); nonfatal myocardial infarction of 5.3, .5, 7.0, and 2.6% (P < .001); stroke of .40, .45, .90, and .90% (P = NS); and additional intervention of 3.8, 11.7, 10.3, and 2.6% (P < .001). CONCLUSION: In this sample, regardless of the treatment previously received patients with or without diabetes and preserved ventricular function experienced similar outcomes. However, patients with ventricular dysfunction had a worse prognosis compared with those with normal ventricular function; patients with diabetes had greater mortality than patients without diabetes. Trial registration http://www.controlled-trials.com. Registration Number: ISRCTN66068876 BioMed Central 2018-03-15 /pmc/articles/PMC5856370/ /pubmed/29568331 http://dx.doi.org/10.1186/s13098-018-0320-y Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Hueb, Thiago
Rocha, Mauricio S.
Siqueira, Sergio F.
Nishioka, Silvana Angelina D´Orio
Peixoto, Giselle L.
Saccab, Marcos M.
Lima, Eduardo Gomes
Garcia, Rosa Maria Rahmi
Ramires, José Antonio F.
Kalil Filho, Roberto
Martinelli Filho, Martino
Impact of diabetes mellitus on ischemic cardiomyopathy. Five-year follow-up. REVISION-DM trial
title Impact of diabetes mellitus on ischemic cardiomyopathy. Five-year follow-up. REVISION-DM trial
title_full Impact of diabetes mellitus on ischemic cardiomyopathy. Five-year follow-up. REVISION-DM trial
title_fullStr Impact of diabetes mellitus on ischemic cardiomyopathy. Five-year follow-up. REVISION-DM trial
title_full_unstemmed Impact of diabetes mellitus on ischemic cardiomyopathy. Five-year follow-up. REVISION-DM trial
title_short Impact of diabetes mellitus on ischemic cardiomyopathy. Five-year follow-up. REVISION-DM trial
title_sort impact of diabetes mellitus on ischemic cardiomyopathy. five-year follow-up. revision-dm trial
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856370/
https://www.ncbi.nlm.nih.gov/pubmed/29568331
http://dx.doi.org/10.1186/s13098-018-0320-y
work_keys_str_mv AT huebthiago impactofdiabetesmellitusonischemiccardiomyopathyfiveyearfollowuprevisiondmtrial
AT rochamauricios impactofdiabetesmellitusonischemiccardiomyopathyfiveyearfollowuprevisiondmtrial
AT siqueirasergiof impactofdiabetesmellitusonischemiccardiomyopathyfiveyearfollowuprevisiondmtrial
AT nishiokasilvanaangelinadorio impactofdiabetesmellitusonischemiccardiomyopathyfiveyearfollowuprevisiondmtrial
AT peixotogisellel impactofdiabetesmellitusonischemiccardiomyopathyfiveyearfollowuprevisiondmtrial
AT saccabmarcosm impactofdiabetesmellitusonischemiccardiomyopathyfiveyearfollowuprevisiondmtrial
AT limaeduardogomes impactofdiabetesmellitusonischemiccardiomyopathyfiveyearfollowuprevisiondmtrial
AT garciarosamariarahmi impactofdiabetesmellitusonischemiccardiomyopathyfiveyearfollowuprevisiondmtrial
AT ramiresjoseantoniof impactofdiabetesmellitusonischemiccardiomyopathyfiveyearfollowuprevisiondmtrial
AT kalilfilhoroberto impactofdiabetesmellitusonischemiccardiomyopathyfiveyearfollowuprevisiondmtrial
AT martinellifilhomartino impactofdiabetesmellitusonischemiccardiomyopathyfiveyearfollowuprevisiondmtrial